Ganirelix
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Ganirelix: From Ovarian Stimulation to Hypertrichosis
One-Sentence Summary
Ganirelix is a GnRH receptor antagonist. The Evidence Pack describes its use in controlled ovarian stimulation, but the US license records list no approved indication text. The TxGNN model predicts it may be effective for hypertrichosis, with a very high score. There are 0 clinical trials and 0 publications for this prediction, so it is a model prediction only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the license data. The Evidence Pack notes use in controlled ovarian stimulation |
| Predicted New Indication | Hypertrichosis |
| TxGNN Prediction Score | 99.98% |
| Evidence Level | L5 |
| US Market Status | ✓ Marketed |
| Number of NDAs | 9 (NDA/ANDA licenses) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Ganirelix is a GnRH receptor antagonist. It blocks GnRH signaling in the pituitary and suppresses LH and FSH, which lowers downstream sex steroids. Detailed mechanism-of-action data from DrugBank are not available in this pack, so this description comes from the pack’s own rationale text.
The link to hypertrichosis is weak. Hypertrichosis is mostly genetic or drug-induced, and no clear pathway connects it to the gonadotropin axis. The only plausible argument is speculative: suppressing androgens might help in hormone-driven hair growth. Even that would not apply to non-hormonal forms.
The score is therefore best read as a knowledge-graph pattern, not a mechanistic finding. Other top predictions are hair-related too (Ambras syndrome, hair shaft abnormality, trichomegaly). This suggests the model is matching shared hair-related phenotypes.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
US Market Information
The license records contain no approved indication text. The table shows the manufacturer instead (5 of 9 licenses listed).
| Authorization Number | Product Name | Dosage Form | Manufacturer |
|---|---|---|---|
| NDA021057 | Ganirelix Acetate | Injection, solution | Organon LLC |
| ANDA214996 | Ganirelix Acetate | Injection, solution | Meitheal Pharmaceuticals Inc. |
| ANDA215658 | Ganirelix Acetate | Injection, solution | Gland Pharma Limited |
| ANDA215658 | Ganirelix Acetate | Injection | Fresenius Kabi USA, LLC |
| ANDA216075 | Ganirelix Acetate | Injection, solution | Lupin Pharmaceuticals, Inc. |
All available products are injectables.
Safety Considerations
- Drug Interactions: The interaction query returned no records.
Please refer to the package insert for warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no trials, no drug-specific literature, and no clear mechanistic link between GnRH antagonism and hypertrichosis. The evidence is model prediction only (L5).
To proceed, the following is needed:
- The FDA package insert (warnings, contraindications, approved indication), which is required before any safety screening
- Detailed mechanism-of-action data from DrugBank
- A biological rationale connecting GnRH/androgen suppression to a specific hormone-driven hypertrichosis subtype
- Consideration of a more plausible candidate from the same prediction set: central precocious puberty (rank 9, score 99.75%), which is GnRH-dependent. It also has no trials or literature, and GnRH agonists are the established standard of care, so any role for a short-acting antagonist would need justification.
Note: the 20 papers retrieved for the rank 3 prediction (a periodontal malformation syndrome) are general periodontitis keyword matches and do not mention ganirelix.
This report is for research reference only and does not constitute medical advice. Repurposing candidates require clinical validation before any use.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.